Disc Medicine, Inc.
Close on Oct 19, 2026
- Market cap
- $3.05B
- P/E (TTM)
- –
- Dividend yield
- –
About Disc Medicine
Pharmaceutical Preparations, SIC 2834
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic treatments for patients suffering from serious hematologic conditions. The company focuses on biological mechanisms regulating red blood cell production and function, specifically targeting heme biosynthesis and iron homeostasis. Its development pipeline includes bitopertin for erythropoietic porphyrias such as erythropoietic protoporphyria and X-linked protoporphyria, DISC-0974 for anemia related to myelofibrosis and inflammatory bowel disease, and DISC-3405 for polycythemia vera and sickle cell disease. Additionally, the company is advancing a preclinical candidate, DISC-0998, for inflammatory anemia. Its target patient population consists of individuals with these blood disorders.
The company conducts its clinical studies within the United States and in foreign countries. It relies on partnerships with external collaborators, including Mabwell and the National Institutes of Health. Disc Medicine does not have approved commercial products, and its principal executive offices are located in Watertown, Massachusetts.
Summary of the business section of Disc Medicine's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Disc Medicine, Inc.
- Headquarters
- Watertown, MA
- Address
- 321 Arsenal Street, Suite 101 02472
- Phone
- (617) 674-9274
- Employees
- 155, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- IRON
- Exchange
- Nasdaq
- IPO date
- Aug 13, 2020
- Shares outstanding
- 38M, Jul 23, 2026
- Public float
- $1.40B, Jun 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 1-for-30 reverse, Dec 30, 2022
- SEC CIK
- 1816736
- CUSIP
- 254604101
- ISIN
- US2546041011
- EIN
- 85-1612845
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| John D. Quisel | Chief Executive Officer, Director | 262,064 |
| Jonathan Yen-Wen Yu | Chief Operating Officer | 63,120 |
| Rahul Khara | Chief Legal Officer | 57,324 |
| Jean M. Franchi | Chief Financial Officer | 64,333 |
| William Jacob Savage | Chief Medical Officer | 81,680 |
| Pamela Stephenson | Chief Commercial Officer | 80,998 |
| Kevin Bitterman | Director | 326,002 |
| Georges Gemayel | Director | – |
| Nadim Ahmed | Director | – |
| Mark Chin | Director | – |
| William Richard White | Director | 0 |
| Liam Ratcliffe | Director | – |
| Donald William Nicholson | Director | 15,332 |
| Mona Ashiya | Director | 186,541 |
| Genesis GP LLC OrbiMed | Director | 941,569 |
| Advisors Llc Orbimed | Director | 5,798,532 |
| Capital GP VIII LLC OrbiMed | Director | – |
| Capital GP VI LLC OrbiMed | Director | 187,297 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Dr. Quisel | $9.99M | $13.48M | $3.83M | $258 | $120 |
| FY2024 Dr. Quisel | $9.07M | $8.67M | $3.83M | $206 | $91 |
| FY2023 Dr. Quisel | $909.10K | $5.23M | $1.22M | $188 | $92 |
| FY2022 Dr. Quisel | $1.83M | $1.18M | $841.28K | $65 | $88 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 155 full-time employees, including 45 who hold Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 29, 2022 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 28, 2022 | Name change | Name changed from Gemini Therapeutics, Inc. /DE to Disc Medicine, Inc. |
| Sep 2, 2022 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Feb 11, 2021 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Feb 11, 2021 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 8, 2021 | Name change | Name changed from FS Development Corp. to Gemini Therapeutics, Inc. /DE |
| Feb 5, 2021 | Delisting | Notice of delisting from exchange (Form 25) |
| Nov 2, 2020 | Merger | Registration of securities for a merger or exchange offer (S-4) |
| Aug 13, 2020 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 10, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |